Bioventis Focus' on Novel Antibiotics
Vienna -Austria's Intercell AG has founded its first spin-off, Biovertis Information Driven Drug Design AG. Intercell is a privately held company, which focuses on the development of vaccines against infectious diseases. The decision to spin off its pipeline research department was prompted by the discovery that one of the company's platform technologies, Antigen Identification Program (AIP), can also be used to develop novel antibiotics.
Intercell will retain its focus on vaccines, while the new company will be free to exploit the full potential of the new application. The parent company has seen Bio-ventis getting a good start by financing the preparation of its R&D programme and business plan. It has recruited its core team from Intercell, including CSO Dr. Uwe von Ahsen. Outlining the strategy, von Ahsen said: “Our goal is to develop new antibio-tics against bacteria that are resistant to existing antibiotic treatments and cause diseases such as respiratory ailments or sepsis.” The company has a close working relationship with the University of Vienna.